Founded in 1949 and domiciled in Galway, Ireland (with principal operational headquarters in Minneapolis, Minnesota), Medtronic plc is the world's largest standalone medical technology company by revenue, serving healthcare systems, physicians, clinicians, and over 82 million patients annually across more than 150 countries. Employing over 95,000 personnel globally, Medtronic develops, manufactures, and markets device-based medical therapies and services that address chronic cardiovascular, neurological, surgical, and metabolic conditions.

Beginning in Q4 FY2026 and formalized in Q1 FY2027 following the March 2026 IPO of MiniMed Group, Inc., Medtronic reorganized its core operations into three main reportable segments while reporting the Diabetes Operating Segment separately pending complete divestiture:

  • Cardiovascular Portfolio: Generated $3,927M in Q1 FY2027 and $13,977M in FY2026, representing Medtronic's largest growth engine.
  • Neuroscience Portfolio: Generated $2,678M in Q1 FY2027 and $10,275M in FY2026, structured across cranial, spinal, neurovascular, and neuromodulation therapies.
  • Medical Surgical Portfolio: Generated $2,279M in Q1 FY2027 and $8,850M in FY2026, focused on surgical instrumentation, endoscopy, and monitoring platforms.
  • Diabetes Operating Segment (MiniMed): Generated $843M in Q1 FY2027 and $3,100M on a standalone basis in FY2026 through 90.03%-owned subsidiary MiniMed Group, Inc.

Rss
Podden och tillhörande omslagsbild på den här sidan tillhör Tim Baker. Innehållet i podden är skapat av Tim Baker och inte av, eller tillsammans med, Poddtoppen.